Lv1
60 积分 2024-12-08 加入
Sensitivity to dabrafenib and trametinib treatments in patients with non-small-cell cancer harboring BRAF compound mutations: A pooled analysis of BRAF p.V600E-positive advanced non-small-cell lung cancer
3个月前
已完结
BRAFN581S and NRASQ61R‐mutated malignant melanoma and sensitivity to BRAF/MEK inhibitors
5个月前
已完结
Two cases of advanced melanoma with BRAF L597 mutation: Options for systemic treatment
6个月前
已完结
Syndrome-causing mutations of theBLMgene in persons in the Bloom's Syndrome Registry
6个月前
已完结
Suppressing tumour Treg cells with a histone demethylase inhibitor
7个月前
已完结
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
7个月前
已完结
皖公网安备34019202002308
